Literature DB >> 3488197

Isoelectric focusing of beta-lactamases from sputum and middle ear isolates of Branhamella catarrhalis recovered in the United States.

D R Nash, R J Wallace, V A Steingrube, P A Shurin.   

Abstract

Branhamella catarrhalis obtained from the sputum of 146 patients with lower respiratory tract disease and from middle ear fluids of 26 children with otitis media were evaluated for beta-lactamase activity and the enzymes were characterised by isoelectric focusing (IEF). 71% (103 of 146) of the sputum isolates and 77% (20 of 26) of the ear isolates produced beta-lactamase. By IEF, the beta-lactamases of 113 of 123 (92%) strains revealed patterns identical with the Ravasio type strain, having unique enzyme bands at pIs of 6.4 and 6.65. The remaining 10 isolates (8%) produced patterns similar to the 1908 type strain with a unique band of activity having a pI of 6.55. In addition, the 1908 types revealed a band of minor enzyme activity with a pI of 7.55 that was absent from the Ravasio types. All strains tested shared major enzyme bands with pIs of 5.1, 5.3, 5.55 and 6.1. These results indicate that the most common beta-lactamase(s) produced by clinical isolates of B. catarrhalis in the United States are similar to those produced by the Belgian Ravasio type strain.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3488197     DOI: 10.2165/00003495-198600313-00012

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  31 in total

1.  Antibacterial activity of the penicillins.

Authors:  M BARBER; P M WATERWORTH
Journal:  Br Med J       Date:  1962-04-28

2.  Novel beta-lactamase from Branhamella catarrhalis.

Authors:  A B Hoi-Dang; C Brive-Le Bouguenec; M Barthelemy; R Labia
Journal:  Ann Microbiol (Paris)       Date:  1978-10

3.  beta-Lactamase-producing Branhamella catarrhalis causing otitis media in children.

Authors:  A L Kovatch; E R Wald; R H Michaels
Journal:  J Pediatr       Date:  1983-02       Impact factor: 4.406

4.  Branhamella catarrhalis pneumonia.

Authors:  M West; S L Berk; J K Smith
Journal:  South Med J       Date:  1982-08       Impact factor: 0.954

5.  Pathogenicity of and beta-lactamase production by Branhamella (Neisseria) catarrhalis.

Authors:  A Percival; J E Corkill; J Rowlands; R B Sykes
Journal:  Lancet       Date:  1977-12-03       Impact factor: 79.321

6.  Bronchopulmonary infection due to Branhamella catarrhalis: 11 cases assessed by transtracheal puncture.

Authors:  G Ninane; J Joly; M Kraytman
Journal:  Br Med J       Date:  1978-02-04

7.  Clinical and microbiological features of Branhamella catarrhalis bronchopulmonary infections.

Authors:  N J Slevin; J Aitken; P E Thornley
Journal:  Lancet       Date:  1984-04-07       Impact factor: 79.321

8.  Bronchopulmonary infection due to Branhamella catarrhalis.

Authors:  D T McLeod; F Ahmad; J T Power; M A Calder; A Seaton
Journal:  Br Med J (Clin Res Ed)       Date:  1983-11-12

9.  Influence of beta-lactamase-producing strains of Branhamella catarrhalis and Haemophilus influenzae on certain beta-lactam antibiotics.

Authors:  J Johnsson; J E Brorson
Journal:  J Antimicrob Chemother       Date:  1983-09       Impact factor: 5.790

10.  Emergence of beta-lactamase-producing strains of Branhamella catarrhalis as important agents of acute otitis media.

Authors:  P A Shurin; C D Marchant; C H Kim; G F Van Hare; C E Johnson; M A Tutihasi; L J Knapp
Journal:  Pediatr Infect Dis       Date:  1983 Jan-Feb
View more
  14 in total

1.  Molecular characterization of the beta-lactamases from clinical isolates of Moraxella (Branhamella) catarrhalis obtained from 24 U.S. medical centers during 1994-1995 and 1997-1998.

Authors:  S S Richter; P L Winokur; A B Brueggemann; H K Huynh; P R Rhomberg; E M Wingert; G V Doern
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

2.  Prevalence of antimicrobial resistance among 723 outpatient clinical isolates of Moraxella catarrhalis in the United States in 1994 and 1995: results of a 30-center national surveillance study.

Authors:  G V Doern; A B Brueggemann; G Pierce; T Hogan; H P Holley; A Rauch
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

Review 3.  [Moraxella catarrhalis: virulence and resistance mechanisms].

Authors:  W Cullmann
Journal:  Med Klin (Munich)       Date:  1997-03-15

4.  Detection of beta lactamase in sputum.

Authors:  C Connell; S Aspinall; J Corkill
Journal:  J Clin Pathol       Date:  1994-08       Impact factor: 3.411

Review 5.  Moraxella catarrhalis: from emerging to established pathogen.

Authors:  Cees M Verduin; Cees Hol; André Fleer; Hans van Dijk; Alex van Belkum
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

Review 6.  Moraxella catarrhalis: clinical significance, antimicrobial susceptibility and BRO beta-lactamases.

Authors:  K McGregor; B J Chang; B J Mee; T V Riley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-04       Impact factor: 3.267

7.  Epidemiological typing of Moraxella catarrhalis by using DNA probes.

Authors:  D Beaulieu; S Scriver; M G Bergeron; D E Low; T R Parr; J E Patterson; A Matlow; P H Roy
Journal:  J Clin Microbiol       Date:  1993-03       Impact factor: 5.948

8.  Use of molecular methods to characterize Moraxella catarrhalis strains in a suspected outbreak of nosocomial infection.

Authors:  M G Morgan; H McKenzie; M C Enright; M Bain; F X Emmanuel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-04       Impact factor: 3.267

9.  Characterization of cell-bound papain-soluble beta-lactamases in BRO-1 and BRO-2 producing strains of Moraxella (Branhamella) catarrhalis and Moraxella nonliquefaciens.

Authors:  I Eliasson; C Kamme; M Vang; S G Waley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-04       Impact factor: 3.267

10.  Mercuric reductase activity and evidence of broad-spectrum mercury resistance among clinical isolates of rapidly growing mycobacteria.

Authors:  V A Steingrube; R J Wallace; L C Steele; Y J Pang
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.